Synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases. However, synuclein c (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly associated with breast cancer progression. Using transgenic mouse model, we demonstrated a role of SNCG in induction of highly proliferative pregnancy-like phenotype of mammary epithelial cells and branching morphology. SNCG participated in the heat shock protein-based multiprotein chaperone complex for steroid receptor signaling. Expression of SNCG in mammary epithelium resulted in a significant stimulation of ERa transcriptional activity. SNCG-induced mammary gland proliferation can be effectively blocked by antiestrogen and ovariectomy, indicating that the induced proliferation is mediated by ERa signaling and requires estrogen stimulation. These data indicate the chaperone activity of SNCG on stimulation of steroid receptor signaling in mammary gland and, thus induces extensive mammary gland proliferation and contributes to the hormonal impact on mammary tumorigenesis.
Introduction
We have previously reported the isolation of differentially expressed genes in the cDNA libraries from normal breast and infiltrating breast cancer using differential cDNA sequencing approach (Ji et al., 1997; Shi et al., 1997; Xiao et al., 1999) . Of many putative differentially expressed genes, a breast cancer specific gene BCSG1 was identified as a putative breast cancer marker. This gene was highly expressed in the advanced breast cancer cDNA library but scarce in a normal breast cDNA library (Ji et al., 1997) . Interestingly, BCSG1 revealed no homology to any other known growth factors or oncogenes. Rather, there is extensive sequence homology to neural protein synuclein. Subsequent to the isolation of BCSG1, synuclein g (SNCG) (Lavedan et al., 1998) and persyn (Ninkina et al., 1998) were independently cloned from a brain genomic library and a brain cDNA library. The sequences of these two brain proteins were found to be identical to BCSG1. Thus, the previously identified BCSG1 has also been named as SNCG and is considered to be the third member of the synuclein family (Clayton and George, 1998) .
Synucleins are a family of small proteins consisting of three known members, synuclein a (SNCA), synuclein b (SNCB) and synuclein g (SNCG). Synucleins have been specifically implicated in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) . Mutations in SNCA is genetically linked to several independent familial cases of PD (Polymeropoulos et al., 1997) . More importantly, wild-type of SNCA is the major component of Lewy bodies in sporadic PD and in a subtype of AD known as Lewy body variant AD (Spillantini et al., 1997; Takeda et al., 1998) . SNCA peptide known as nonamyloid component of plaques has been implicated in amyloidogenesis in AD (Ueda et al., 1993; Yoshimoto et al., 1995) . SNCB and SNCG have also been recognized to play a role in the pathogenesis of PD and Lewy bodies cases (Galvin et al., 1999; Duda et al., 2000) . Although synucleins are highly expressed in neuronal cells and are abundant in presynaptic terminals, they have also been implicated in non-neural diseases, particularly in the hormone responsive cancers of breast (Ji et al., 1997 (Ji et al., , 1999 Jiang et al., 2003 Jiang et al., , 2004 Inaba et al., 2005; Wu et al., 2003 Wu et al., , 2006 Gupta et al., 2003a, b) and ovary (Lavedan et al., 1998; Bruening et al., 2000; Liu et al., 2000; Lu et al., 2000; Pan et al., 2002; Gupta et al., 2003a) .
Being identified as a breast cancer specific gene, SNCG expression in breast follows a stage-specific manner (Ji et al., 1997) . Overall SNCG mRNA expression was detectable in 39% of breast cancers. However, 79% of stage III/IV breast cancers were positive for SNCG expression, while only 15% of stage I/II breast cancers were positive for SNCG expression.
In contrast, the expression of SNCG was undetectable in all benign breast lesions (Wu et al., 2003) . Overexpression of SNCG in breast cancer cells led to a significant increase in cell motility and invasiveness in vitro and a profound augmentation of metastasis in vivo (Jia et al., 1999) , resistance to chemotherapeutic druginduced apoptosis (Pan et al., 2002; Gupta et al., 2003a, b) , and accelerated rate of chromosomal instability (Gupta et al., 2003a, b; Inaba et al., 2005) . Overexpression of synucleins, especially SNCG, also correlated with ovarian cancer development (Lavedan et al., 1998; Bruening et al., 2000) . While synucleins (a, b, and g) expression was not detectable in normal ovarian epithelium, 87% (39 of 45) of ovarian carcinomas were found to express either SNCG or SNCB, and 42% (19 of 45) expressed all three synucleins (a, b and g) simultaneously. The involvement of SNCG in hormone responsive cancers of breast and ovary promoted us to explore the potential role of SNCG in cellular response to estrogen. Previously, we investigated the functions of SNCG in regulating ERa transcriptional activity in human breast cancer cells in vitro. Augmentation of SNCG expression in breast cancer cells stimulated the transcriptional activity of ERa, whereas compromising endogenous SNCG expression suppressed ERa signaling (Jiang et al., 2003) . In the present study, we evaluated the in vivo function of SNCG in mammary gland development and the relevance of stimulation of ERa signaling to mammary pathogenesis. The results indicated that SNCG, acting as a chaperone protein for ERa, stimulates steroid receptor signaling in mammary epithelial cells, and induces a highly proliferative pregnancy-like phenotype.
Results

Effects of expression of SNCG transgene on mammary gland development
We generated five SNCG transgenic lines and picked up one stable line named MMS1, which expressed relative high level of SNCG. Transgene expression in the mammary gland was assayed by RT-PCR and Western analyses (Figure 1 ). In the mammary glands from virgin MMS1 mouse, the expression of the transgene was detected by RT-PCR using the primers specific for human SNCG (Figure 1a) . No signal was detected in the mRNA isolated from mammary glands of virgin wildtype females. Consistent with the transgene mRNA expression, while no SNCG protein was detected in the gland from the virgin control females, SNCG protein was highly expressed in the mammary gland from MMS1 mouse (Figure 1b ). Both MMS1 mice and mice from other transgenic lines developed normally compared with their nontransgenic littermates.
The effect of transgene expression on mammary gland development was assayed by morphological analyses of ductal elongation and appearance of a branching morphogenesis. While the mammary gland development starts at about 3-week old in wild-type mice with ductal elongation, development of branching structure and functional differentiation starts at the onset of pregnancy with the expansion of secretory lobular-alveolar architecture. Whole mount preparations of the mammary glands starting at 4-week to 8-week from virgin wild-type and virgin transgenic mice were examined to determine the effect of SNCG on early mammary gland development. Figure 2 shows a representative mammary gland analysis of 7-week old transgenic mouse vs wildtype control littermate. Mammary ducts in the transgenic virgin (Figure 2b ) as well as in the control virgin littermate (Figure 2a ) passed the typical half the length of the inguinal gland, completely filled with the ducts, and appeared normal. Similar ductal developments were also observed at different time points, indicating that expression of the transgene did not alter the ductal outgrowth during the early mammary gland development. However, an alternation in the developmental pattern of the branching points of ducts in transgenic virgin mouse was observed compared with the control littermate. While the limited branching was developed in the wild-type gland (Figure 2a) , transgenic gland exhibited a multiplicity of branching (Figure 2b ).
Induction of highly proliferative pregnancy-like phenotype proliferation To further confirm our observation of induced branching morphology in SNCG transgenic mouse, we extended the whole mount mammary gland analysis starting at 2-month to 5-month from virgin wild-type and virgin transgenic mice to determine the effect of SNCG on development of proliferative branching morphology. Two mice were examined for each time point and data in Figure 2c- the wild-type gland (Figure 2c and e), transgenic gland at 3-month exhibited an increased branching morphology and end bud density (Figure 2d ). A robust increase in the branching structure at terminal end was observed in the gland from 5-month virgin transgenic mouse (Figure 2f ), a phenotype similar to the stage of pregnancy. The increased branching in the transgenic mice suggests a potential effect of SNCG on induction of proliferation of mammary epithelial cells in the end bud. We analysed the effect of SNCG on mammary epithelial cell proliferation in the transgenic mouse. We measured the percentage of cycling cells determined by BrdU incorporation in three 3-month old SNCG transgenic mice and the three age-matched control mice. While the average percent of labeled nuclei in control mice was 7.1%, expression of SNCG significantly stimulated cell proliferation with a 42% of nuclei labeled cells (Table 1) . These observations are consistent with our in vitro data indicating SNCG stimulates ligand-dependent growth of human breast cancer cells (Jiang et al., 2003) .
Histological evaluation of H&E-stained mammary sections also confirmed the presence of multiple branching structures in the gland from the virgin transgenic mice. There were no morphological differences observed in the younger (4-to 6-week old) transgenic mice compared to the age-matched control mice. However, starting at 10-week old, a significantly different morphology was observed in the transgenic mice vs the control mice. As shown in Figure 3 , whereas no branching structures were present in the 3-month old control virgin mouse, indicating no proliferation of end BrdU was injected i.p. at a dosage of 75 mg/kg into wild-type and transgenic mice. After 2 h, the mice are killed, and the right third inguinal glands are removed and processed for BrdU analysis. Tissues are fixed, processed and sectioned. BrdU is detected using a 1:400 dilution of a rat monoclonal antibody specific for BrdU (Accurate Chemicals) and avidin-biotin complex immunohistochemistry. The percentage of labeled nuclei is determined by randomly counting 500 epithelial cells in five fields ( Â 40) with three observers. Numbers are means7s.d. of three mice.
bud ( Figure 3a ), a branching morphology (Figure 3b -c) was observed in the transgenic mice, indicating a highly proliferative capability of cells in the terminal end buds. A representative robust branching development was observed in a 5-month old transgenic mouse and illustrated in Figure 3d . Histological analysis also revealed the presence of hyperplasia-like structure in the transgenic mouse ( Figure 4 ). Epithelium of transgenic glands exhibits a disorganized structure with respect to the ordinate arrangement of the wild-type epithelium. Furthermore, while a normal mammary gland has a single layer of epithelial cells (Figure 4a ), gland from transgenic mouse displayed a highly proliferative stage characterized by areas of multilayered epithelium ( Figure 4b ). No carcinoma was observed in the virgin transgenic mice up to 1 year.
Stimulation of ERa signaling in mammary epithelial cells by SNCG
As expression of SNCG in mammary gland resulted in highly proliferative mammary epithelial cells in the end bud, we interested in study whether stimulation of ERa signaling is one of targets for SNCG in normal Table 1 . Inguinal glands were isolated and sections were subjected to both hematoxylin stain for histological analysis and to immunohistochemical stain with rat monoclonal antibody specific for BrdU for reviewing labeled nuclei. Nuclei labeled with brown color indicate proliferating cells. Open arrow indicates normal mammary gland. Solid arrow indicates a hyperplasia-like structure in the transgenic mouse. mammary epithelial cells and in vivo effect on mammary gland proliferation. Using MCF-12A human mammary epithelial cells, we first determined if expression of SNCG would physically interact with ERa by coimmunoprecipitation assay. MCF-12A cells were transiently transfected with either the pCI-SNCG expression plasmid or control pCI-neo plasmid. In the absence of estrogen, immunoprecipitation of ERa co-precipitated SNCG and Hsp90 ( Figure 5a ) and immunoprecipitation of SNCG co-precipitated ERa and Hsp90 (Figure 5b ), indicating that SNCG participated in a heterocomplex with Hsp90 and ERa in the absence of estrogen. However, SNCG dissociated from ERa after the cells were treated with E2. The binding pattern of SNCG to the unliganded ERa is same to that of Hsp90, which only binds to the unliganded ERa (Pratt and Toft, 1997) . Similar to its binding pattern to ERa, SNCG also only bound to Hsp90 in the absence of estrogen. After cells were treated with E2, the liganded ER-a dissociated from SNCG and Hsp90. We next investigated if SNCG functionally stimulates ERa signaling. Transfection of SNCG gene into MCF-12A cells did not affect ERa expression (Figure 5c ), which suggesting that overexpression of SNCG did not affect ERa expression levels. Transfection of SNCG significantly stimulated E2-mediated activation of ERa (Figure 5d ). Treatment of wild-type and SNCG transfected MCF-12A cells with E2 resulted in a significantly differential increase in estrogen-responsive reporter ERE4-Luciferase (ERE4-Luc) activity relative to basal levels in untreated cells. Overexpression of SNCG gene in MCF-12A cells increased E2-stimulated reporter activity 5.2-fold over the SNCG-negative control cells. The SNCG-stimulated transcriptional activity of ER-a was ligand-dependent, because SNCG had no significant effect on the transcriptional activity of ER-a in the absence of E2.
Stimulation of ERa signaling in transgenic mammary gland
We next investigated the effect of SNCG on ERa signaling in mammary gland, which was measured by analysis of ER-mediated transcriptional activity on E 2 -regulated genes of PS2 and Cathepsin D (Cat-D). Figure 6 shows a representative real time RT-PCR analysis of ERa, PS2 and Cat-D mRNA expression in three virgin control mice and three age-matched virgin transgenic mice. While basal levels of PS2 and Cat-D were detected in control mice, forced expression of SNCG in virgin mammary glands significantly enhanced PS2 and Cat-D expression, resulting in an average 3.4-fold ( Figure 6b ) and 4.8-fold (Figure 6c ) increase over control mice, respectively. There was no significant change in ERa expression in control vs transgenic mice (Figure 6a ), indicating that the increased PS2 and Cat-D expression in the transgenic mice is mediated by enhanced ER signaling but not due to the alternation of ER levels. To avoid the different in vivo estrogenic environments due to the different hormonal cycling of mice, we used whole mammary organ culture to study whether E2 can differentially regulate Cat-D expression in glands from control and transgenic mice. In this ex vivo model, the glands from virgin mice were cultured for 8 days to deplete the endogenous hormones before the E2 treatment. Expression of SNCG was clearly detectable in the glands from transgenic mouse in this short-term organ culture (Figure 7a The transfected cells were selected with G418 and then transfected with pERE4-Luc as well as control reporter pRL-SV40-Luc. After transfection, cells were cultured in the ligand-free medium for 4 days as described in Materials and methods, treated with or without 1 nM E2 for 24 h before the promoter activities were determined by measuring the dual luciferase activity. The ERE reporter luciferase activity was normalized against the control renilla luciferase activity to correct for transfection efficiency. All values were presented as the fold induction over the control luciferase activity in the non-treated SNCG-negative cells, which was taken as 1. The numbers represent means7s.d. of three cultures.
E2 treated transgenic gland, resulting in a 5.4-fold increase over the E2 treated control gland (Figure 7b ).
Inhibition of SNCG-stimulated mammary gland proliferation by ERa antagonist and alternation of endogenous levels of estrogen As a chaperone protein participated in Hsp-based multichaperone complex, SNCG regulates (chaperoning) many pathways in growth and progression of cancer. To determine if SNCG-induced mammary gland proliferation is mediated by its chaperone activity on stimulation of ERa signaling, we studied the requirement of function of ERa and presence of E2 for SNCGmediated effect on mammary gland proliferation. We analysed mammary proliferation and morphology by treatment of transgenic mice with tamoxifen and reducing endogenous levels of estrogen using ovariectomized mice. As expected, tamoxifen treatment and particularly ovariectomy reduced proliferation of mammary epithelial cells in control mice. Expression of SNCG in mammary gland significantly stimulated proliferation resulting in a 5.4-fold increase over control mice, both ovariectomy and tamoxifen treatment completely blocked SNCG-induced stimulation on cell proliferation, bringing BrdU labeling index even below control mice (Figure 8 ). Alternated morphological phenotype also confirmed the reduction in cell proliferation. While SNCG stimulated a robust increase in the branching structure at terminal end in the transgenic mouse (Figure 9b ), the extensive branching morphology disappeared when transgenic mouse ovariectomized (Figure 9c ) or treated with tamoxifen ( Figure 9d ). These data suggest that SNCG-induced mammary gland proliferation is mediated by ERa signaling and requires estrogen stimulation. Quantitative RT-PCR analysis of ERa, PS2 and Cat-D expression. Inguinal mammary glands were isolated from agematched virgin control and SNCG mice. Mice from Con1 and SNCG1 were 13-weeks old. Mice from Con2 and SNCG2 were 16-week old. Mice from Con3 and SNCG3 are 18-week old. RNAs were isolated and subjected to real-time PCR analysis using the TaqMan PCR core reagent kit (Applied Biosystems). Relative expressions of mouse ERa, PS2 and Cat-D gene in the mammary glands from SNCG mice were calculated in comparison to that from Con1 mouse, which was taken as 100% and regarded as control. All the other values were expressed as a percentage of the control. The mouse beta actin gene was used as endogenous control. The numbers represent the means7s.d. of duplicate RNA samples.
Discussion
Synucleins are small proteins expressed predominately in neurons and have been specifically implicated in the neurodegenerative disorders such as AD and PD. However, SNCG was first identified and cloned as a breast cancer specific gene, which is highly expressed in advanced infiltrating breast carcinomas but not in normal or benign breast tissues (Ji et al., 1997; Wu et al., 2003) . Aberrant expression of SNCG was also associated with ovary cancer progression (Lavedan et al., 1998; Bruening et al., 2000) . The association between SNCG expression and the progression of steroid dependent cancers of breast and ovary suggest a potential role of SNCG in regulation of ERa. Previously, we demonstrated an SNCG-stimulated ERa signaling in human breast cancer cell (Jiang et al., 2003) . Functionally, SNCG significantly stimulates hormone-dependent growth of breast cancer cells both in vitro and in nude mice (Jiang et al., 2004) . A notable finding in this study is that SNCG, acting as a chaperone protein participated in Hsp-based multiprotein chaperon complex for steroid receptors, induced extensive mammary gland proliferation, which is mediated by its stimulation of ligand-dependent transcriptional activity of ERa in mammary gland. Expression of SNCG in mammary gland in the virgin mouse greatly stimulated the proliferation of the mammary cells at end bud and resulted in a robust morphological branching, a phenotype similar to the pregnancyinduced proliferation. The identification of steroid receptors of ERa as molecular target for one of the actions of SNCG on the hormone-dependent growth of mammary gland suggest a critical role of SNCG on the pathogenesis of mammary tumors. There are two distinct patterns of growth and development in mammary gland. The first involves the penetration of the mammary fat pad by branching ductal morphogenesis and the second involves the growth and expansion of mammary cells at the end bud and formation of differentiated lobule alveoli at the onset of pregnancy. While the ductal elongation is the normal mammary development before the onset of pregnancy, proliferation of end bud cells and formation of lobule alveoli is the consequence of functional multihormonal impact induced by pregnancy. In the transgenic gland, SNCG-stimulated robust proliferation of mammary epithelial cells at the end bud could be manifested by two different hormonerelated mechanisms: stimulation of steroid hormone receptor signaling activity and local increase of estrogenic hormones or combination of both. In vitro studies using human breast cancer cells, we have demonstrated convincing data showing the chaperone activity of SNCG on stimulation of ERa transcriptional activity and E2-stimulated growth. As stimulation of ERa transcriptional activity by SNCG was also demonstrated in mammary gland, we believe that the same mechanism also applies to the normal mammary epithelial cells in the transgenic mouse model. In this regard, enhancement of ERa activity by SNCG will sensitize ERa response to estrogenic hormones and thus results in an enhanced hormonal environment and the induction of estrogen-mediated proliferation and mammary gland. Indeed, we demonstrated that inhibition of ERa function by tamoxifen or reducing endogenous levels of estrogen by using ovarectomized mice can completely blocked SNCG-induced gland proliferation, indicating the requirement of functional ERa. However, although we did not observe an increase in systematic levels of plasma estrogen in transgenic mouse vs control mouse (data not shown), it is possible that local intramammary levels of estrogen could be alternated. This becomes an increasingly important issue in an assessment of estrogen levels. While plasma E2 levels decrease at menopause by about 90%, breast tissue E2 levels are maintained at nearly the same level as seen in premenopausal women (Geisler, 2003) . As plasma estrogen levels do not reflect tissue estrogen levels, it is becoming very important to measure the intratissue levels of estrogen. However, using SNCG transfected MCF-7 cells, our initial studies indicated that there was no physical interaction between SNCG and aromatase and no stimulation of aromatase activity could be measured (data not shown). Thus, we believe that chaperoning of ERa signaling rather than alternation of intramammary estrogen metabolism is the underlying mechanism for induced gland proliferation.
Hsp-based chaperone complex regulates many steroid hormone receptors including androgen receptor, progesterone receptor and glucocordicoid receptor in addition to ERa. As a chaperone protein participated in Hsp-based chaperone complex, SNCG may also regulate other steroid hormone receptors besides ERa. We previously investigated the effect of SNCG on the transcriptional activity of ERb. In contrast to the demonstrated stimulation of ERa signaling, SNCG did not stimulate the transactivation of ER-b (Jiang et al., 2004) . However, since expression of SNCG in mammary gland stimulated a significant proliferation of end bud cells and a robust morphological branching, a phenotype resembles early pregnancy, steroid receptors involved in mammary expansion during pregnancy, such as PR, may also be a target for SNCG's action for induction of highly proliferative status in virgin gland of the transgenic mouse. It is noteworthy although SNCG does not induce spontaneous mammary tumor in virgin mouse up to 12 month, it might induce tumors by multiple pregnancy due to the robust hormonal (estrogen and progesterone) stimulation at the onset of pregnancy.
Although mutations in SNCA have been detected in several cases of familial Parkinson's disease (Polymeropoulos et al., 1997) , the malignant phenotype in breast cancer is correlated with the high level expression of wild-type SNCG protein. Analysis of breast tumor samples did not identify any sequence variation of SNCG gene from its original neuronal environment and no gene amplification was detected either (Ninkina et al., 1998) . Therefore, the aberrant expression of SNCG in breast carcinomas is caused by transcriptional activation of the gene. By analysing the promoter region of SNCG and conducting genomic sequencing, we demonstrated that the loss of methylation control in a CpG island located in exon 1 of SNCG was primarily responsible for its aberrant expression in human breast cancer (Lu et al., 2001; Gupta et al., 2003a, b) . The loss of epigenetic control of SNCG by demethylation was also demonstrated in ovarian cancers (Gupta et al., 2003a, b) . The most recent publication further indicated a universal loss of the epigenetic control of SNCG by demethylation of CpG sties within the CpG island of SNCG gene in a variety of different human carcinomas including liver, esophagus, color, gastric, lung, prostate and cervical . Since expression of SNCG gene is usually not detectable in normal non-neoplastic epithelial cells, its stage-specific expression in breast cancer strongly suggest that reactivation of SNCG by DNA demethylation is a common critical contributing factor for onset and malignant progression of breast cancer. We demonstrated here that expression of SNCG in mammary gland stimulates ER signaling and induces extensive mammary gland proliferation. Our findings suggest that SNCG functions as a chaperone and participates in Hsp-based multiprotein chaperone system for efficient activation of ERa. It has previously been demonstrated in human breast cancer cells that the interaction between SNCG and ER-a stimulated cell growth in response to estrogen (Jiang et al., 2003) . In addition, SNCG overexpression significantly stimulated the tumorigenesis of MCF-7 cells in response to estrogen, while it has no effect on tumor growth in the absence of estrogen. Consistent with the requirement of E2 for SNCG-stimulated tumor growth, we also demonstrated that SNCG has no significant effect on tumor growth of ERa-negative MDA-MB-435 cells (Jia et al., 1999) . These data clearly demonstrated a role of SNCG on stimulation of ligand-dependent ERa signaling in breast cancer cells and in normal mammary gland.
It is noteworthy that the role of SNCG in mammary carcinogenesis is also involved in non-ER-mediated functions. As a chaperone protein, SNCG regulates (chaperoning) many pathways in growth and progression of cancer. On the basis of our data and others, besides stimulation of steroid receptor signaling, SNCG has several major functions associated with tumorigenesis. First, SNCG is a candidate pro-metastatic mediator during breast cancer malignant progression. Expression of SNCG in breast cancer cells leads to a significant increase in motility and invasiveness in vitro and a profound augmentation of metastasis in nude mice (Jia et al., 1999) . Consistent with the ability to confer metastatic potential to breast cancer cells, we recently demonstrated that patients with SNCG-positive breast cancer have statistically higher incidence for metastasis compared with patients with SNCG-negative cancer (Wu et al., 2006) . In addition, a recent study also indicates a strong association between SNCG protein expression in primary tumors and distant metastasis in diversified cancer types, including liver, esophagus, colon, gastric, lung, prostate, cervical and breast cancer . Second, SNCG may contribute tumorigenesis by promoting genetic instability. SNCG physically interacts with mitotic checkpoint protein BubR1 in breast cancer cells (Gupta et al., 2003a, b) . We demonstrated that SNCG expression in breast cancer cells overrides the mitotic checkpoint control and the inhibitory effects of SNCG on mitotic checkpoint can be overthrown by enforced overexpression of BubR1 in SNCG-expressing cells (Inaba et al., 2005) . These data suggest that SNCG expression compromises the mitotic checkpoint control by inhibition of the normal function of BubR1, thereby promoting genetic instability. Third, SNCG confers cellular resistance to induced apoptosis (Pan et al., 2002) . SNCG expressing cells are significantly more resistant to the chemotherapeutic drugs compared with the SNCG-negative cells. In the present study, we demonstrated ERa as one of the critical target molecules for SNCG's action in normal mammary epithelial cells: turning normal mammary gland into a highly proliferative stage. Thus, aberrant expression of SNCG stimulates breast cancer development and progression, at least in part, by enhancing the transcriptional activity of ERa. The loss of epigenetic control by demethylation of SNCG gene can be used as s sensitive molecular tool in early detection in morphologically normal tissues before tumors emerge. Development of SNCG as a biomarker for breast cancer early diagnosis and progression warrants further investigation.
Materials and methods
DNA constructions and generation of transgenic mice
The MMTV regulatory sequences were derived from the plasmid pMMTV/MRG that previously used for MRG transgenic mice (Wang et al., 2003) . The full-length SNCG cDNA sequence from pCI-SNCG (Jia et al., 1999) was subcloned into the BamHI and ApaI sites of the MMTV plasmid. To ensure proper expression of this cDNA, SV40 splicing and polyadenylation signals were added to the 3 0 portion of the construct. A 2.5 kb MMTV-SNCG transgene was separated from the vector and isolated from an agarose gel. The DNA fragments were injected into fertilized eggs (5 ng/ml) of FVB/N mouse. Injected cells were transferred into the oviduct of pseudopregnant ICR female mice and allowed to develop to term. At 6 weeks after microinjections of MMTV/SNCG transgene, 30 newborn mice were generated and screened by Southern blot. Five transgenic mice were identified. Mating founder animals to wild-type (FVB/n background) male and female generated four first-generation transgenic lines. Transgenic males and females from the same family were mated to generate homozygous mice. If a mouse produced two or more litters of offspring that were transgenic, the mouse was considered to carry the transgene. Homozygous male and female mice from the same family were mated to each other to maintain the homozygous lines.
Whole mount histological analysis of mammary gland Whole inguinal mammary glands were removed from virgin control as well as virgin transgenic mice. The removed gland was subjected to whole mount fix, defat and staining as previously described (Wang et al., 2003) . Briefly, the inguinal mammary glands were fixed in 75% EtOH, 25% HoAC and stained with alum carmine (0.1% w/v). Whole mount glands were destained in 70, 90 and 100% EtOH, respectively, defatted in xylenes, and stored in methyl salicylate.
Mammary gland organ culture A pair of whole inguinal mammary glands was removed from 14-week virgin female mice (FVB/n background) as previously described (Wang et al., 2000) . The glands were cultured in phenol red-free medium 199 containing 5% charcoal-stripped FCS, with medium changed every 2 days. The medium was supplemented with following components from Clonetics: bovine pituitary extract (52 mg/ml), insulin (5 mg/ml), EGF (10 ng/ml) and hydrocortisone (1 mg/ml).
Gene transfection, immunoprecipitation and Western Blot
Gene transfection, immunoprecipitation and Western blot were conducted as we previously described (Jiang et al., 2003) .
Assays for the transcriptional activity of ER-a Cells were transiently transfected with a firefly luciferase reporter construct (pERE4-Luc) containing four copies of the estrogen response element (ERE). For the co-transfection experiments, the plasmid DNA ratio of pERE4Luc to expression vectors of SNCG was 2:1. A renilla luciferase reporter, pRL-SV40-Luc, was used as an internal control for transfection efficiency. Luciferase activities in total cell lysate were measured using the Promega Dual Luciferase Assay System as previously described (Jiang et al., 2003) . Absolute ERE promoter firefly luciferase activity was normalized against renilla luciferase activity to correct for transfection efficiency. Triplicate wells were assayed for each transfection condition and at least three independent transfection assays were performed.
Conditioned cell culture
Proliferating subconfluent MCF-12A human mammary epithelial cells were harvested and cultured in the phenol redfree IMEM containing 5% charcoal-stripped fetal calf serum for 3 days, and then in 1% charcoal-stripped FCS and phenol red-free IMEM for 1 day before addition of E2. Cells in the absence or presence of E2 were collected 24 h after addition of hormone and were subjected to the assays for ERa transcriptional activity.
Quantitative RT-PCR analyses RNA was isolated and subjected to real-time PCR analysis using the TaqMan PCR core reagent kit (Applied Biosystems, Foster City, CA, USA) and ABI Prism 7700 Sequence Detection System (Applied Biosystems). Data were analysed using Sequence Detection System (SDS) software version 1.6.3. Results were obtained as Ct (Threshold cycle) values. C t is inversely proportional to the starting template copy number. Relative expressions of mouse PS2, ERa and Cat-D gene in the mammary glands from SNCG transgenic mice or the gland treated with E2 were calculated in comparison to that from control mouse using delta Ct method (User Bulletin #2, Applied Biosystems).
Abbreviations AD, Alzheimer's disease; BCSG1, breast cancer specific gene 1; Cat-D, Cathepsin D; ERa, estrogen receptor a; Hsp, heat shock protein; PD, Parkinson's disease; PR, progesterone receptor; SNCA, a synuclein; SNCB, b synuclein; SNCG, g synuclein.
